Article
A new platform for high-throughput therapy testing on iPSC-derived lung progenitor cells from cystic fibrosis patients.
Stem cell reports - 9 Nov 2021
Jiang Jia Xin, Wellhauser Leigh, Laselva Onofrio, Utkina Irina, Bozoky Zoltan, Gunawardena Tarini, Ngan Zoe, Xia Sunny, Di Paola Michelle, Eckford Paul D W, Ratjen Felix, Moraes Theo J, Parkinson John, Wong Amy P, Bear Christine E
Abstract excerpt
For those people with cystic fibrosis carrying rare CFTR mutations not responding to currently available therapies, there is an unmet need for relevant tissue models for therapy development. Here, we describe a new testing platform that employs patient-specific induced pluripotent stem cells (iPSCs) differentiated to lung progenitor cells that can be studied using a dynamic, high-throughput fluorescence-based...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.